ProShares Ultra NASDAQ Biotechnology
BIB
19 hedge funds and large institutions have $3.4M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
1% less call options, than puts
Call options by funds: $2.23M | Put options by funds: $2.27M
2.21% less ownership
Funds ownership: 6.07% → 3.85% (-2.2%)
21% less funds holding
Funds holding: 24 → 19 (-5)
39% less capital invested
Capital invested by funds: $5.59M → $3.4M (-$2.19M)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.51M |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$58.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$41.8K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
+$26.6K |
| 5 |
AWM
Activest Wealth Management
Aventure,
Florida
|
+$19.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.68M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$735K |
| 3 |
Jane Street
New York
|
-$290K |
| 4 |
MCC
Money Concepts Capital
Palm Beach Gardens,
Florida
|
-$202K |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$30.2K |
BIB Hedge Fund Activity: Q3 2022 in Review
19 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2022, worth a combined $3.4M — down 39% from $5.59M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BIB and 1 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Susquehanna International Group, adding an estimated $1.51M. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.68M sold.
- 19 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2022, down from 24 in Q2 2022.
- Funds reported $3.4M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2022, down 39% quarter-over-quarter.
- 1 fund opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2022 and 6 closed out, a net change of -5 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2022 was Susquehanna International Group, an estimated $1.51M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2022 was Citadel Advisors, an estimated $2.68M sold.
Based on aggregated 13F filings for Q3 2022.